---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-24-000065"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:52:26.375420+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akebia Q2 2024 net loss narrows to $8.6M; Vafseo launch on track for Jan 2025

## Summary
- Total revenues $43.6M (down 23% YoY); Auryxia net product rev $41.2M vs $42.2M in Q2 2023.
- Net loss $8.6M vs $11.2M in Q2 2023; cash and equivalents $39.5M as of June 30, 2024.
- Vafseo TDAPA application submitted; HCPCS codes expected Oct 2024, TDAPA by Jan 2025.
- Set Vafseo WAC at $1,278 for 30-day supply (~$15,500/year); regained full U.S. rights from CSL Vifor.
- Auryxia FY 2024 net product revenues expected in line with 2023 level ($167M in 2023).

## SEC filing metadata
- accession: 0001517022-24-000065
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000065/0001517022-24-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000065/akba-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-24-000065
- JSON: https://secwatch.observer/filing/0001517022-24-000065.json
- Plain text: https://secwatch.observer/filing/0001517022-24-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.